Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Oct 07, 2024
NEU continues PMS P3 preparations after positive FDA meeting
Aug 27, 2024
H1 2024 financial results
Aug 27, 2024
Half Yearly Report and Accounts
Aug 19, 2024
Investor roadshow presentation, 19 August 2024
Aug 16, 2024
Change of Director's Interest Notice - J Basile
Aug 09, 2024
NNZ-2591 Angelman top-line results presentation
Aug 09, 2024
Phase 2 trial shows significant improvements in Angelman
Aug 07, 2024
Trading Halt
Aug 07, 2024
Pause in Trading
Aug 07, 2024
Q2 2024 update
1
2
3
4
5
Next
